Log In Sign up
The largest database of trusted experimental protocols

Camptosar

Manufactured by Pfizer
Visit Supplier

Camptosar is a product line of laboratory equipment used for scientific research and analysis. It provides essential tools and instruments for various applications in the life sciences, chemical, and pharmaceutical industries. The core function of Camptosar products is to facilitate and support scientific investigations, data collection, and experimental procedures within controlled laboratory environments.

Automatically generated - may contain errors

Lab products found in correlation

Gemzar, by Eli Lilly (1 mentions) Brain derived neurotrophic factor (bdnf), by Thermo Fisher Scientific (1 mentions) Irinotecan, by Roche (1 mentions) Capecitabine, by Roche (1 mentions) Avastin, by Genentech (1 mentions)

6 protocols using camptosar

1

Combination Chemotherapy Protocols for NSCLC

Check if the same lab product or an alternative is used in the 5 most similar protocols
The PT-DC regimens used for our patients included pemetrexed (PEM, Alimta, Eli Lilly, Indianapolis, IN) and cisplatin (DDP, Qilu Pharmaceutical Co. Ltd, Jinan, China), gemcitabine (GEM, Gemzar, Eli Lilly) and DDP, irinotecan (CPT-11, Camptosar, Pfizer, New York, NY) and DDP, PEM and nedaplatin (NDP, Simcere Pharmaceutical Groups, Nanjing, China), and GEM and NDP. PEM was administered intravenously (via IV) at 500 mg/m2 on day 1; DDP and NDP were administered via IV at 75 mg/m2 on day 1; GEM was administered via IV at 1250 mg/m2 on days 1 and 8; and CPT-11 was administered via IV at 60 mg/m2 on days 1, 8, and 15. Endostatin (Endostar, Simcere Pharmaceutical Groups) was infused via IV at 7.5 mg/m2 once daily for 14 days along with PT-DC therapy. Cycles were repeated every 21 days (PEM/GEM plus DDP/NDP) or 28 days (CPT-11 plus DDP) until disease progression or unacceptable toxicity were reached. Patients who received 4 or more cycles of therapy were designated as the extended therapy group, while those who received less than 4 cycles of therapy were designated as the control group. During the treatment, concurrent radiotherapy was performed based on the judgments of the treating physicians. For patients who developed progression, EGFR tyrosine kinase inhibitors (TKIs), or docetaxel-based chemotherapy were used for subsequent treatment.
Hu W., Fang J., Nie J., Dai L., Zhang J., Chen X., Ma X., Tian G., Wu D., Han S., Han J., Wang Y, & Long J. (2016). Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine, 95(28), e4183.
+ Open protocol
+ Expand
2

Irinotecan and SN38-Tocopherol Succinate Nanoparticles for Tumor Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
SN-38 was developed and evaluated as a chemotherapeutic agent, but it was both toxic and not water soluble, so irinotecan was later introduced as its water-soluble prodrug. Irinotecan (Camptosar, Pfizer) is a commercially available, orally bioavailable topoisomerase I inhibitor that is used clinically for a variety of tumor types. It is converted by carboxylesterase converting enzyme into SN38, its active metabolite. Irinotecan (20 mg/ml) was diluted in 0.9% normal saline and administered by oral gavage once daily at 10 mg/kg, Monday through Friday, for either 4 weeks or 8 weeks. Saline was used as the control. The SN38-Tocopherol Succinate (SN38-TS) NPs were administered at an effective dose of 10 mg/kg SN38. The SN38-TS NPs were given via tail vein injection either once every other week, once per week, or twice per week (Monday/Wednesday), for 4 or 8 weeks. Irinotecan was obtained from the pharmacy at The Children’s Hospital of Philadelphia. The doses used in this study were based on prior published studies (7 (link)). Human brain-derived neurotrophic factor (BDNF; PeproTech, Rock Hill, NJ) was reconstituted in distilled water at 2 µg/ml. For long-term storage in −20°C, the reconstituted BDNF was further diluted to 1µg/ml and used at a final concentration of 100 ng/ml.
Iyer R., Croucher J.L., Chorny M., Mangino J.L., Alferiev I.S., Levy R.J., Kolla V, & Brodeur G.M. (2015). Nanoparticle Delivery of an SN38 Conjugate is More Effective Than Irinotecan in a Mouse Model of Neuroblastoma. Cancer letters, 360(2), 205-212.
+ Open protocol
+ Expand
3

Metastatic Colorectal Cancer Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
As recommended by the guidelines of the National Comprehensive Cancer Network, patients were allocated to FU-based treatment. FOLFIRI, irinotecan (Camptosar; Pfizer) 180 mg/m2 intravenous (IV) infusion over 30–90 minutes, day 1; leucovorin 400 mg/m2 IV infusion to match the duration of irinotecan infusion, day 1; 5-FU 400 mg/m2 IV bolus, day 1; then 1200 mg/m2/day × 2 days (total 2400 mg/m2 over 46–48 hours) continuous infusion; repeat every 14 days or mCapeIRI35 (link) regimen (irinotecan 125 mg/m2, days 1 and 8; capecitabine (Xeloda; Roche)825–1000 mg/m2, twice daily on days 1–14; repeat every 21 days) or FOLFOX (oxaliplatin 80 mg/m2 IV infusion over 2 hours, day 1; leucovorin 400 mg/m2 IV over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus, day 1; then 1200 mg/m2/day × 2 days continuous infusion; repeat every 14 days) or CapeOX (Oxaliplatin 130 mg/m2 day 1, capecitabine 825–1000 mg/m2, twice daily on days 1–14; repeat every 21 days) or single-agent chemotherapy of capecitabine (1250 mg/m2 twice daily on days 1–14; repeat every 21 days). All patients accepted 5-hydroxytryptamine receptor antagonist (5 mg once a day) 30–60 minutes before irinotecan or oxaliplatin. The chemotherapy continued until disease progressed or intolerable toxicities came out or patients asked to withdrew due to any reason.
Huang L., Chen F., Chen Y., Yang X., Xu S., Ge S., Fu S., Chao T., Yu Q., Liao X., Hu G., Zhang P, & Yuan X. (2014). Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines. Scientific Reports, 4, 5697.
+ Open protocol
+ Expand
4

Intravenous Administration of Irinotecan

Check if the same lab product or an alternative is used in the 5 most similar protocols
Irinotecan (CPT-11; 20 mg/mL; Camptosar, Pfizer) was obtained from the pharmacy at The Children’s Hospital of Philadelphia (CHOP, Philadelphia, PA) and was diluted in 0.9% normal saline before being administered intravenously.
Nguyen F., Alferiev I., Guan P., Guerrero D.T., Kolla V., Moorthy G.S., Chorny M, & Brodeur G.M. (2018). Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(11), 2585-2593.
+ Open protocol
+ Expand
5

Bevacizumab and Irinotecan for Recurrent GBM

Check if the same lab product or an alternative is used in the 5 most similar protocols
Treatment consisted of biweekly cycles of bevacizumab (Avastin; Genentech) and irinotecan (Camptosar; Pfizer). Bevacizumab is a full-length recombinant humanized monoclonal antibody that was designed to bind and inhibit the vascular endothelial growth factor. It was given accelerated approval by the U.S. Food and Drug Administration in May 2009 for the treatment of recurrent GBM. Irinotecan is a prodrug that is converted by esterases (primarily in the liver) to its more potent phenolic form, SN-38. Both the parent drug and SN-38 can bind to topoisomerase I after it complexes with DNA, preventing repair of single-strand breaks caused by topoisomerase I. This complex of irinotecan or SN-38 with the topoisomerase and DNA is cytotoxic to the cell, which is both its therapeutic mechanism of action and the mechanism of action for its toxicity [30 ]. Treatment with both agents continued until the patient experienced any signs of clinical or radiographic disease progression. All 21 enrolled patients finished the first course of 6 weeks. No patient was lost to follow-up.
Wardak M., Schiepers C., Cloughesy T.F., Dahlbom M., Phelps M.E, & Huang S.C. (2014). 18F-FLT and 18F-FDOPA PET Kinetics in Recurrent Brain Tumors. European journal of nuclear medicine and molecular imaging, 41(6), 1199-1209.
+ Open protocol
+ Expand
6

Irinotecan-Equivalent Nektar Therapeutics EP

Check if the same lab product or an alternative is used in the 5 most similar protocols
EP (Nektar Therapeutics, San Francisco, CA) was dissolved in 5% dextrose in water adjusted to a final pH of 5.20–5.86. To facilitate direct comparison with irinotecan, all EP doses are expressed as irinotecan-equivalent unit delivered in the conjugated form. Irinotecan (Camptosar®, Pfizer, Groton, CT) was also prepared by dissolution in 5% dextrose in water, and final pH was adjusted to 4.61–4.85. The control solution contained only the vehicle, which was 5% dextrose in water.
Sy S.K., Sweeney T.D., Ji C., Hoch U, & Eldon M.A. (2016). Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. Cancer Chemotherapy and Pharmacology, 79(1), 57-67.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!